Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence G Lum

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 5, 2011
Targeting T cells with bispecific antibodies for cancer therapyLawrence G Lum, Archana Thakur
Cancer Treatment Reviews|April 13, 2010
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedAbhinav Deol, Lawrence G Lum
Current Opinion in Hematology|October 13, 2015
Activated T cells armed with bispecific antibodies kill tumor targetsDivaya Bhutani, Lawrence G Lum
Expert Opinion on Biological Therapy|February 6, 2016
"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical ResultsArchana Thakur, Lawrence G Lum
Oncoimmunology|May 4, 2016
<i>In Situ</i> immunization by bispecific antibody targeted T cell therapy in breast cancerArchana Thakur, Lawrence G Lum
Current Opinion in Molecular Therapeutics|June 4, 2010
Cancer therapy with bispecific antibodies: Clinical experienceArchana Thakur, Lawrence G Lum
Expert Opinion on Drug Discovery|March 20, 2013
Development and prospects for bispecific antibody-based therapeutics in cancer and other applicationsLawrence G Lum, Zaid Al-Kadhimi
Expert Opinion on Biological Therapy|May 14, 2019
Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needsLaahn H Foster, Lawrence G Lum
Cancer Cell|May 11, 2021
Arming "old guards" with "new dual-targeting weapons"Lawrence G Lum, Jogender Tushir-Singh
Expert Opinion on Biological Therapy|July 29, 2024
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignanciesDaniel R Reed, Lawrence G Lum
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 5, 2011
Targeting T cells with bispecific antibodies for cancer therapyLawrence G Lum, Archana Thakur
Cancer Treatment Reviews|April 13, 2010
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedAbhinav Deol, Lawrence G Lum
Current Opinion in Hematology|October 13, 2015
Activated T cells armed with bispecific antibodies kill tumor targetsDivaya Bhutani, Lawrence G Lum
Expert Opinion on Biological Therapy|February 6, 2016
"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical ResultsArchana Thakur, Lawrence G Lum
Oncoimmunology|May 4, 2016
<i>In Situ</i> immunization by bispecific antibody targeted T cell therapy in breast cancerArchana Thakur, Lawrence G Lum
Current Opinion in Molecular Therapeutics|June 4, 2010
Cancer therapy with bispecific antibodies: Clinical experienceArchana Thakur, Lawrence G Lum
Expert Opinion on Drug Discovery|March 20, 2013
Development and prospects for bispecific antibody-based therapeutics in cancer and other applicationsLawrence G Lum, Zaid Al-Kadhimi
Expert Opinion on Biological Therapy|May 14, 2019
Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needsLaahn H Foster, Lawrence G Lum
Cancer Cell|May 11, 2021
Arming "old guards" with "new dual-targeting weapons"Lawrence G Lum, Jogender Tushir-Singh
Expert Opinion on Biological Therapy|July 29, 2024
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignanciesDaniel R Reed, Lawrence G Lum
Pageof 9